DASL technology was used to quantify mRNA in samples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer ( North Central Cancer Treatment Group N9831 [ NCCTG-N9831 ] ) adjuvant trastuzumab trial .